ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in...
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its...
ORANGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2024 financial...
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) , a neurotech company...
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets,...
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced...
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK, 18 October 2024 – ViaNautis Bio (“ViaNautis” or...
RIYADH, Saudi Arabia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is contributing to...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR...
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence,...
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets,...
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be...
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an...
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has...
ALISO VIEJO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Laguna Treatment Center is among an elite group of addiction treatment...
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data...
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
SCOTTSDALE, Ariz., Oct. 17, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers...
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is...